Peptide News Digest

#CGRP

7 stories

CGRP — calcitonin gene-related peptide — is the migraine target that opened the modern migraine therapeutics market (erenumab, fremanezumab, galcanezumab, and the gepant small molecules). Coverage on this site has shifted recently as GLP-1 drugs have shown migraine benefit in head-to-head and registry analyses.

The most cited 2026 read: AAN 2026 reported that GLP-1 agonists cut migraine ED visits 10% and hospitalizations 14% versus topiramate in a 22,000-patient comparative study, plus a 42% reduction in CGRP monoclonal antibody starts. The overlap raises questions about whether GLP-1s, gepants, and CGRP antibodies sit in additive or competitive positions for chronic migraine. On October 1, 2026, Lundbeck reported that in its open-label Phase 4 THRIVE trial, 60% of 164 adults whose migraine had responded inadequately to one prior CGRP-targeting preventive rated themselves much or very much improved after 24 weeks on Vyepti (eptinezumab).

Stories here cover the migraine peptide pipeline and the GLP-1 spillover. See #migraine for the indication and #gepants for small-molecule CGRP antagonists.

Research · View digest

Review: Evidence for CGRP Migraine Drugs in Children Rests on One Randomized Trial and a Handful of Real-World Studies

A narrative review published October 14, 2026 in Current Pain and Headache Reports found that the evidence for CGRP-targeting migraine treatments in people under 18 consists of one randomized controlled trial, of fremanezumab (Ajovy) in children aged 6 to 17 with episodic migraine, which showed benefit, plus several small real-world studies. CGRP drugs have been used in adults since 2018, and the authors said trials of other CGRP-targeting drugs in children are still pending.

Research · View digest

Copenhagen REFORM Study Finds Blood Amylin Levels Do Not Distinguish Migraine or Predict Response to Erenumab

Researchers at the Danish Headache Center reported in Headache on October 13, 2026 that plasma amylin, a hormone closely related to the migraine signal CGRP, did not differ between 121 adults with migraine and 63 healthy controls (about 9 ng/mL in each group), across migraine subtypes, or between people who did and did not respond to 24 weeks of the CGRP-blocking antibody erenumab (Aimovig); levels also did not change during treatment. The authors concluded that blood amylin is not a useful migraine biomarker, though amylin drugs such as pramlintide can still trigger attacks.

Clinical Trials · View digest

Lundbeck's Vyepti Leaves 60% of Migraine Patients 'Much Improved' After a Prior CGRP Drug Fell Short, in Open-Label Phase 4 THRIVE Trial

Lundbeck reported headline results on Thursday, October 1, 2026 from THRIVE, an open-label Phase 4 trial of Vyepti (eptinezumab), an antibody against the neuropeptide CGRP, in 164 adults with at least eight monthly migraine days whose migraine had responded inadequately to one prior CGRP-targeting preventive, either a subcutaneous antibody or a gepant. Patients received 100 mg at baseline and 300 mg at week 12; at week 24, 60% rated themselves much or very much improved on the Patient Global Impression of Change scale, up from 44% at week 12, and 84% completed the study. There was no placebo group, and Lundbeck said no new safety signals were seen.

Research · View digest

AAN 2026: GLP-1 Agonists Cut Migraine ED Visits 10%, Hospitalizations 14% vs Topiramate in 22,000-Patient Study

A presentation at the American Academy of Neurology 2026 meeting (closing April 22) reported that in 10,997 chronic migraine patients initiating GLP-1 agonists versus an equal topiramate cohort, GLP-1 users were 10% less likely to visit the ED (23.7% vs 26.4%), 14% less likely to be hospitalized, 42% less likely to start CGRP monoclonal antibodies, and 48% less likely to start valproate over 12 months — adding migraine to the growing list of GLP-1 secondary benefits.